Simplify MAb Production by Eliminating Contaminating IgG and Reducing Cost
InVitria and Lampire to Host Webinar on Monoclonal Antibody Production
MAbs are a valuable asset in the development of future of medicines, from use as basic research tools to large-scale biotherapeutics. Given the versatility and convenience offered by using hybridomas to produce MAbs, scientists continue to expand upon the vast potential these proteins represent. However, limitations in hybridoma productivity and costly purification processes associated with contaminating materials, such as IgG from bovine serum used in hybridoma culture medium, can significantly increase MAb costs.
During this webinar, the challenges facing non-therapeutic MAb production will be discussed. Annette Flood, Monoclonal Department Manager, Lampire Biological Laboratory will present a case study to show Lampire’s success in reducing costs and improving performance in serum-free hybridoma cell culture conditions and Mab production.
“The development of technologies to improve the consistency and purification of monoclonal antibody production is key to reducing manufacturing costs,” said Brittany Medbery, InVitria. “In this webinar we will share the successful implementation of this technology.”
To sign up for the webinar “Serum-Free Cell Culture Can Cost Less: Simplify MAb Production by Eliminating Contaminating IgG and Reducing Cost”, register here.
About Lampire Biological Laboratory - www.lampire.com
Lampire Biological Laboratory is a privately owned company founded in Pennsylvania over 30 years ago specializing in polyclonal and monoclonal antibody development, cell culture services, a wide variety of human and animal blood-derived products, purified IgGs, plus a comprehensive line of animal tissues and organs. Lampire is committed to consistently providing the highest quality, most reliable products and services possible in conformity with our customers’ requirements, specifications, and standards.
For additional information, contact Lampire at 215-795-2838 or visit their website www.Lampire.com.
InVitria develops, manufactures, and markets a portfolio of products used in cell culture, diagnostics, and bioproduction. InVitria’s products address customer needs for defined, animal component free cell culture supplements in stem cell technology, regenerative medicine, biomanufacturing, diagnostics, biopharmaceutical formulation, cell-based vaccines, and general life science research.
Visit us online at www.InVitria.com.
Press releases you might also be interested in
Weitere Informationen zum Thema "Biotechnology":
Smart Cities knacken 2025 weltweit die 2-Billionen-Dollar-Marke
Das Marktforschungsunternehmen Frost & Sullivan prognostiziert für die Smart City goldene Zeiten. Im Jahr 2025 soll sie Geschäftsmöglichkeiten im Wert von zwei Billionen US-Dollar generieren. In der Hauptrolle der Smart Cities: Künstliche Intelligenz.Weiterlesen